TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6122937
Drug: Beta adrenoceptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta adrenoceptor blocking drugs
Study: 30519893
Drug: Cefuroxime bolus-continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime bolus-continuous infusion targeting free serum cefuroxime concentrations of 64 mg/L
Study: 28120603
Drug: High-dose nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nebulized budesonide
Study: 26591686
Drug: Yi Zhi
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yi Zhi Chan Tuina manipulation with 2 min treatment time
Study: 20060945
Drug: IC41 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC41 vaccine
Study: 16927534
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of lithium carbonate 300 mg
Study: 12782436
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulfate applied topically to the ulcer
Study: 10947689
Drug: Intravenous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous epinephrine (15 microg)
Study: 6581064
Drug: Fenoterol powder
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol powder (0.2 mg)
Study: 6581064
Drug: Fenoterol aerosol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol aerosol (0.2 mg)
Study: 26722003
Drug: Aspirin pretreatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin pretreatment
Study: 22669347
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine 0.1 mg/kg with nasal and IM placebo
Study: 22669347
Drug: IM morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM morphine 0.1 mg/kg with nasal and IV placebo
Study: 18201659
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection of corticosteroids, local anesthetic, and contrast dye from anterolateral, lateral, or posterior locations
Study: 18201659
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection of corticosteroids, local anesthetic, and contrast dye
Study: 16025045
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid use
Study: 16234044
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg (tablet) for patients aged 12 years or older, 200 mg (oral suspension) for patients aged 4-11 years, 100 mg (oral suspension) for patients aged 1-3 years, administered twice daily for 3 days.
Study: 7954760
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) 1620 mg lysine acetylsalicylate (equivalent to 900 mg aspirin) combined with 10 mg metoclopramide
Study: 7954760
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP)
Study: 3653766
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 60 mg/m2 every 3 weeks
Study: 3653766
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, doxorubicin, and cisplatin (CAP)
Study: 25885677
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (40 mg daily for 5 days)
Study: 22845184
Drug: Written plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written plus oral information before colonoscopy
Study: 22845184
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information before colonoscopy
Study: 21266792
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA, 10 mg/day)
Study: 21266792
Drug: Lynestrenol (LYN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynestrenol (LYN, 15 mg/day)
Study: 21266792
Drug: Norethisterone (NET,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone (NET, 15 mg/day)
Study: 11777668
Drug: Buspirone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone and group therapy (12-week double-blind placebo-controlled trial)
Study: 8424014
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine anesthesia (0.2 to 0.5 mL)
Study: 26414973
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg melatonin before bedtime
Study: 16828475
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection 3-4 hours earlier (Group C)
Study: 16828475
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection at the same interval (Group B)
Study: 16828475
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection with >or=47% immature oocytes (Group A)
Study: 8581442
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (50 degrees F) for THA patients
Study: 8581442
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (not specified for TKA)
Study: 8581442
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy and Control for both THA and TKA patients
Study: 19346521
Drug: Candesartan-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan-based therapy
Study: 19220756
Drug: R-137696 2
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-137696 2 mg t.i.d. for 4 weeks
Study: 17224029
Drug: Fully rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully rough implants (FR)
Study: 15222523
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% hyperbaric bupivacaine + 20 mg of fentanyl (Group F)
Study: 15222523
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% hyperbaric bupivacaine + 0.4 ml normal saline (Group S)
Study: 12667371
Drug: Routine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine group (dehydrant, antihypertensive agent, etc.)
Study: 1958119
Drug: Linsidomine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsidomine (0.8 mg)
Study: 1958119
Drug: Nitroglycerin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.15 mg)
Study: 19815152
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at 1 hour before separator placement, 400 mg of ibuprofen at 3 hours and 7 hours after placement (Group B)
Study: 11500337
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial prophylaxis (gentamicin/colistin/vancomycin 2% in Orabase, every 6 h)
Study: 11500337
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial prophylaxis
Study: 10204257
Drug: Rescue treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment
Study: 2660902
Drug: Intensive sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive sequential chemotherapy
Study: 23578031
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg
Study: 19692680
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg per day)
Study: 24043283
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg, then 0.6 mg/kg for 4 more days)
Study: 11092169
Drug: Adenosine, adenosine-receptor-agonists,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine, adenosine-receptor-agonists, and dipyridamole prior to coronary angioplasty
Study: 11092169
Drug: Glibenclamide (sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (sulfonylurea drug therapy)
Study: 9096687
Drug: Standard-dose mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose mitoxantrone (12 mg/m2 on days 1-3) with cytarabine (3 g/m2 on days 1-5)
Study: 1558794
Drug: High-dose mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mitoxantrone
Study: 9096687
Drug: Standard-dose mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose mitoxantrone
Study: 8415897
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg paroxetine per day
Study: 8078953
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amitriptyline per day
Study: 3003728
Drug: Enalapril (injection)
Normalized name: enalapril Injectable Solution
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (injection)
Study: 29096426
Drug: RG7342 (0.06-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7342 (0.06-1.2 mg)
Study: 2520622
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide 50 mg t.d.s. for 1 month
Study: 11829370
Drug: Oral anti-emetics
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-emetics (maxolon)
Study: 26782247
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen via a facemask at a constant flow rate of 3 l/min (O2 group)
Study: 20478580
Drug: Surveillance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surveillance with antibiotics only for symptomatic urinary tract infection
Study: 9288517
Drug: Cold antegrade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold antegrade St. Thomas II cardioplegic solution
Study: 9288517
Drug: Bretschneider cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretschneider cardioplegic solution
Study: 9288517
Drug: Hamburg cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamburg cardioplegic solution
Study: 8385552
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol HCL 100 mg (Group A)
Study: 3943275
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of alanine
Study: 26049730
Drug: Transvenous vagus
Normalized name: Sus scrofa vagus nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvenous vagus nerve stimulation (tVNS) for 30 minutes (0-10 V, 1 ms, 20 Hz) starting 10 minutes before LPS administration (2 ng kg(-1) Escherichia coli lipopolysaccharide)
Study: 19455196
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment in dialysis unit
Study: 16980747
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha (40,000 IU weekly)
Study: 16980747
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (RBV dose reduction from 1000/1200 to 800/600 mg)
Study: 2888421
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine
Study: 3553135
Drug: ceftizoxime (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftizoxime (2-4 g every 8 h)
Study: 24868083
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg with either atenolol 50 mg or hydrochlorothiazide 12.5 mg)
Study: 20199139
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg once daily for 16 days, then tapered to 5 mg for 14 days
Study: 20199139
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily for 16 days, then tapered to 30 mg for 14 days
Study: 21960068
Drug: Dorzolamide/timolol-fixed combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol-fixed combination (DTFC)
Study: 15969661
Drug: Salmeterol 50μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50μg twice daily in addition to fluticasone 200μg
Study: 12121563
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of allopurinol (AL) at 20 mg/kg/day plus low-dose MA at 30 mg/kg/day for 20 days
Study: 7732340
Drug: Mesalazine suppositories
Normalized name: mesalamine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine suppositories
Study: 21156071
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30-70 mg/d
Study: 23356790
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) (all doses)
Study: 17577644
Drug: NP101 (iontophoretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP101 (iontophoretic sumatriptan patch)
Study: 17577644
Drug: NP101 (iontophoretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP101 (iontophoretic sumatriptan patch) delivering 6 and 12 mA per h
Study: 17577644
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg subcutaneous injection of sumatriptan
Study: 17577644
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral tablet of sumatriptan succinate
Study: 15734604
Drug: Premelle 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premelle 2.5 mg (0.625 mg conjugated estrogen + 2.5 mg medroxyprogestorone)
Study: 15734604
Drug: Kliogest (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kliogest (2 mg estradiol + 1 mg norethisterone)
Study: 15734604
Drug: Livial (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livial (2.5 mg tibolone)
Study: 7582401
Drug: Niceritrol (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niceritrol (750 mg/day)
Study: 7582401
Drug: Niceritrol (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niceritrol (750 mg/day) after fluvastatin (30 mg/day)
Study: 7582401
Drug: Niceritrol (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niceritrol (750 mg/day) and Fluvastatin (30 mg/day)
Study: 29702271
Drug: Hyoscine-N-Butylbromide (HBB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine-N-Butylbromide (HBB) 20 mg
Study: 18791718
Drug: Tocosol Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocosol Paclitaxel (175 mg/m2, 15 min intravenous infusion)
Study: 18791718
Drug: Taxol (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol (175 mg/m2, 3 h intravenous infusion)
Study: 14726744
Drug: No Immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Immunoglobulin (Ig) therapy
Study: 8571936
Drug: rh IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh IFN alpha‐2b (150 x 10(4) IU: 3 MIU) administered three times a week
Study: 8571936
Drug: Any administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any administration schedule of rh IFN alpha‐2b
Study: 8571936
Drug: Once a
Normalized name: Once A Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a week administration schedule of rh IFN alpha‐2b
Study: 2018005
Drug: 5-hydroxypropafenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxypropafenone (300 mg, single oral dose)
Study: 7036279
Drug: Adriamycin-cyclophosphamide (AC)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin-cyclophosphamide (AC) chemotherapy
Study: 7036279
Drug: AC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC chemotherapy plus comprehensive regional radiotherapy
Study: 31095313
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein Hydrolysate (WPH) 0.08 g/kg BW
Study: 26075373
Drug: NPWT (negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWT (negative pressure wound therapy)
Study: 9602957
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg, 800 mg, 1,200 mg once daily
Study: 9602957
Drug: Eprosartan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (various doses)
Study: 29232162
Drug: Ly‐Lis (Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ly‐Lis (Insulin Lispro)
Study: 23211877
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg daily aglycone hypocotyl soy isoflavone supplementation
Study: 15020520
Drug: Glibenclamide 10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 10.5 mg
Study: 14578240
Drug: Multidisciplinary diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary diabetes outreach service (six monthly visits by a traveling team of specialist physicians, nurses, dieticians, and a pharmacist)
Study: 11176729
Drug: High-dose lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lisinopril
Study: 8210967
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of lovastatin combined with 10 g of colestipol
Study: 2946972
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg with 5 ml of 1% xylocaine
Study: 2946972
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with normal saline 5 ml followed by xylocaine
Study: 15737773
Drug: Concomitant vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant vaccination with Recombivax HB, Td, and MMR vaccines
Study: 19293008
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (400 mg/kg/d for 5 days)
Study: 8550251
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg per os)
Study: 2213104
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (control)
Study: 2213104
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (both arms)
Study: 2213104
Drug: Orchiectomy (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy (initial endocrine therapy)
Study: 2213104
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) (initial endocrine therapy)
Study: 8589000
Drug: G‐CSF
Normalized name: Granulocyte colony-stimulating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF
Study: 22422824
Drug: G‐CSF with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF with escalated-dose cytarabine
Study: 18503773
Drug: Peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2a 180 mug/wk plus ribavirin 1000/1200 mg/day for 24 weeks
Study: 15924511
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise therapy (n = 87)
Study: 10947756
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 7.5 mg combined with preservative‐free ketamine 25 mg
Study: 10947756
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 10 mg alone
Study: 1502426
Drug: Nimodipine therapy
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine therapy in addition to standard therapy
Study: 6488686
Drug: Diazepam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3 mg/kg) before ketamine
Study: 30807424
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (2% transurethral)
Study: 30059794
Drug: medications (d-cycloserine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: medications (d-cycloserine, alprazolam)
Study: 24844787
Drug: PC-SOD (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SOD (80 mg, intravenous)
Study: 19497461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nurse assessment and MMX result
Study: 7555933
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy and laser photocoagulation
Study: 1362432
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy
Study: 1780416
Drug: Overall treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatments (Nicotine, Silver Acetate, Ordinary chewing gum)
Study: 28791802
Drug: Immediate-release prednisolone
Normalized name: prednisolone Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release prednisolone
Study: 24080993
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 1000 mg plus prednisone 5 mg b.i.d.
Study: 24080993
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus prednisone 5 mg b.i.d.
Study: 23419915
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of estimation accuracy between individual therapy sessions and circuit class therapy